Evinova conducted a Phase II COPD study using a remote connected spirometer paired with AI-validated overreads and the CompEx digital endpoint to enable live, continuous monitoring instead of a fixed observation schedule.
Public source
Publisher name
Public post
Could a digital endpoint mean fewer patients? This week at #ERS2026 trial design is top of mind for respiratory disease researchers. Here's a case study worth a look: in…
Company
Evinova
Global healthtech
- Industry
- Software Development
- Company size
- 201–500 employees
About Evinova
Digital solutions need to do more to propel clinical development, elevate user experiences and accelerate better health outcomes. At Evinova, we’re doing something about it. We’re a healthtech business, with globally-scaled digital products that have proven benefits for sponsors, sites and patients. We've accelerated timelines, improved patient experiences, reduced costs, and minimised carbon footprints across hundreds of clinical studies. Evinova is a 300+ person strong team offering digital solutions to pharma, biotech and CROs to support clinical research globally. Community Guidelines: http://bit.ly/3JIeErQ
See moreLatest activity
Latest activity from Evinova
13 signals
Research & Knowledge
Evinova found that 50% fewer patients were needed in a Phase II COPD study compared to a traditional design.
Research & Knowledge
Evinova found that 50% fewer in-person visits were needed in the Phase II COPD study.
Research & Knowledge
Evinova achieved a $8m reduction in study costs in the Phase II COPD study.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
PONS
PONS published a paper by Evinova's president reviewing AZ protocols across oncology, respiratory and cardiovascular disease concluding that 74 to 85 percent of trial assessments could be collected remotely, cutting clinical visits by up to 40 percent, published in Nature Medicine in 2023.
Research & Knowledge
Castor
Castor closed enrollment for a fully virtual, direct-to-patient study three months ahead of schedule.
Research & Knowledge
Fivos
Fivos reduced costs by $45 million by leveraging real-world registry data across six industry studies.
Research & Knowledge
Thirona
Thirona published findings from the 10-year COPDGene study showing that LungQ® automated measurements demonstrated a strong association between longitudinal airway changes and COPD progression with significantly higher mucus plug burden observed over time in patients with progressive disease.
Research & Knowledge
electronRx